T he adverse effects of prenatal marijuana use remain unclear (1) , yet more pregnant women are using marijuana in the United States than ever before (2, 3) . Self-reported marijuana use during pregnancy increased from 2.4% in 2002 to 3.9% in 2014 (2) , and 18% of pregnant women who used marijuana in the past year met criteria for a marijuana use disorder (4) . Data from a large, diverse sample of pregnant women and adolescents in California found an increase in the adjusted prevalence of marijuana use, from 4% in 2009 to 7% in 2016, on the basis of self-report and urine toxicology tests. Overall, 22% of adolescents and 19% of young adults had screening results positive for prenatal marijuana use in 2016 (3) . Approximately twice as many users were identified by toxicology tests than self-report, suggesting that prenatal use has been underestimated in selfreported surveys (3) .
Despite this apparent widespread and increasing use of marijuana during pregnancy (2), the specific effects on mothers and their offspring are unclear. Although some evidence exists that marijuana use during pregnancy may be associated with reduced fetal growth and development (including lower neonatal birthweight) and certain neurocognitive impairments (1, 5) , associations with most fetal, neonatal, and childhood outcomes are largely inconclusive (1) . This uncertainty is partly a result of the limitations of existing research, including small sample sizes in most studies, and thus low power to detect associations; reliance on self-reports of marijuana use; and inattention to the mode of marijuana administration, which may moderate any health effects. Differentiation of marijuana smoking versus other forms of administration during pregnancy is particularly needed, because research has shown that many of the well-known adverse health effects of prenatal tobacco smoking are mediated by the vascular effects of smoke, and marijuana smoking may confer similar risks. Moreover, most previous studies did not fully account for important confounding factors (such as poverty, intimate partner violence, and other types of substance use during pregnancy) and lacked the power to examine a subgroup of women who use marijuana only. A recent systematic review and meta-analysis indicated that maternal prenatal marijuana use may not be an independent risk factor for adverse neonatal outcomes after controlling for concurrent tobacco use and other confounding factors; however, the meta-analysis was underpowered to detect associations (6) . In addition, the negative impact of concurrent marijuana and other substance use on fetal and neonatal outcomes may be greater than the effect of either drug on its own (6) . Because of such limitations, isolating marijuana-specific effects is difficult.
In the Table, we present new data on the high rate of substance co-use in a cohort of pregnant patients in the Kaiser Permanente Northern California health system who were universally screened for any prenatal substance use by self-report and urine toxicology from 2009 to 2016 (3). More than a third of the women who had a screening result positive for marijuana use also had a positive result for at least 1 other substance, highlighting the importance of controlling for cooccurring prenatal substance use to accurately detect marijuana-specific health risks.
An urgent need exists to understand the effects of prenatal marijuana exposure, because it may continue to rise in conjunction with the growing acceptance, accessibility, and spread of legalization in the United States. Meeting this need requires well-designed retrospective and prospective cohort studies in current, large, representative populations, using validated measures of marijuana exposure and adjusting for other types of substance use. Health care systems with large samples of diverse pregnant patients and centralized electronic health records are particularly well positioned to conduct this research, because data from mothers and their offspring can be linked easily and membership retention of children in integrated health care delivery systems is quite This article was published at Annals.org on 21 August 2018. 
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high. In addition, large health care systems are now capturing data on important potential confounding variables, such as exposure to intimate partner violence and measures of neighborhood deprivation. Guidelines from the American College of Obstetricians and Gynecologists strongly recommend that clinicians screen for and advise against marijuana use during pregnancy (5), but pregnant women themselves perceive a lack of evidence about the harms of prenatal marijuana use, expressing dissatisfaction with the quality of evidence available and a desire for better information (7) . Investment in rigorous studies that characterize and quantify the health risks associated with prenatal marijuana use and include data on mode of marijuana administration, dosage, and trimester of use may provide findings with immediate clinical implications that could be actively disseminated to clinicians and patients. If adverse effects are substantiated, such evidence-based information might help change the perception that marijuana use during pregnancy carries little risk. This is important because evidence exists that women who quit using marijuana during pregnancy are more likely than those who do not to believe that prenatal marijuana may be harmful (8) . Likewise, it is imperative that any evidence of risks not be exaggerated.
Perhaps of most importance, we believe that every woman deserves nonpunitive health care so that she can access services that support a substance-free pregnancy. Although 9 states and the District of Columbia have legalized both recreational and medical marijuana use, and 20 have legalized purely medical marijuana use (9), child welfare laws have not kept up with the new legislation. Instead, in many states, substance use during pregnancy is considered grounds for termination of parental rights or even incarceration (10) . Currently, California is the only state in which a positive toxicology screening result in pregnancy is not sufficient grounds to make a child abuse or neglect report. We believe it is critical that research on prenatal marijuana use and its effects on health not be exploited to penalize or stigmatize women, but instead be used to empower them to make informed decisions about marijuana use during pregnancy.
From Kaiser Permanente Northern California, Oakland, California (N.G., A.C., K.C.Y.).
